We are a biopharma company that partners with top-tier researchers to accelerate new discoveries in the world of medicine, one powerful idea at a time!
It’s always nice to be mentioned with $NVDA… “This treatment is particularly special, as according to the firm, it is the first human data from a genetically modified #T-Cell vaccine.’ #biopharma#discovery$oceafinance.yahoo.com/news/13-ho…
Congratulations to our partners at Virion for solid Phase 1 study data, the first ever for a checkpoint modifier containing T cell vaccine of any kind. We are proud of this groundbreaking work towards creating a functional cure for #HBV! $oceabit.ly/3vliYdn
EXCLUSIVE: Ocean Biomedical Announces Publication of Breast Cancer Research On New Tumor Suppression Pathway for Proprietary Antibody $OCEAbenzinga.com/general/biotech… via @Benzinga
Today, @WHO published the World Malaria Report
📑 which explores the impacts of climate change on #malaria transmission. Robust surveillance 📈 is critical in ensuring malaria programmes can respond to the impact of changing weather.
Read more 📰#COP28brnw.ch/21wETZV
ALT The image shows a street covered in rainwater.
The text reads
"World Malaria Report: Beyond the numbers, new approaches needed to accelerate progress."
Ocean Biomedical CEO, Elizabeth Ng, CFO Gurinder Kalra, and Executive Chairman, Chirinjeev Kathuria will be presenting today at 12:35pm... Presenting on the Emerging Growth Conference 64 Day 1 on November 1 globenewswire.com/news-relea…$ocea
We're in! 🍾 First patients dosed in Hong Kong today in a groundbreaking, international HBV study with our partner Virion Therapeutics, evaluating a new "functional cure" for chronic Hep B infection. #FPI#HBV#biopharma$OCEAbit.ly/3s5WmvI